Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer, accounting for 85% of cases of lung cancer. NSCLC is commonly treated with cisplatin, however, NSCLC develops resistance to cisplatin via several mechanisms, which reduces treatment efficacy and becomes a major challenge in its treatment. Several plant extracts have been researched as potential anticancer, includi…
Lung cancer is the most malignant tumor with the highest mortality in the world. Early diagnosis and prognosis are important to improve the patient’s survival rate. With AI, screening which is one of the methods of detection is more sensitive and accurate allowing better analysis. This will in turn assist medical professionals in their line of work and improve the medical field overall. Th…
Non-small-cell lung cancer (NSCLC) comprises the majority of lung cancer about 75-80%, and a quarter of NSCLC cases have mutations in the epidermal growth factor receptor (EGFR) gene. Adenocarcinomas of the lung harboring the L858R mutation in exon 21 have proven to be more adverse in terms of prognosis than exon 19 mutations. Therefore, developing highly sensitive and selective methods to …